Neutropenia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neutropenia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Pegfilgrastim for Patients with Severe Chronic Neutropenia https://clinicaltrials.eu/trial/study-on-pegfilgrastim-for-patients-with-severe-chronic-neutropenia/ Wed, 29 Apr 2026 15:03:33 +0000 https://clinicaltrials.eu/trial/study-on-pegfilgrastim-for-patients-with-severe-chronic-neutropenia/ This clinical trial is focused on studying a condition known as severe chronic neutropenia (SCN). This is a disorder where the body has a lower than normal number of a type of white blood cell called neutrophils, which are important for fighting off infections. The treatment being tested in this study is a medication called pegfilgrastim, which is marketed under the name Neulasta. Pegfilgrastim is a type of medicine known as a colony-stimulating factor, which helps the body produce more neutrophils.

The purpose of the study is to evaluate how effective pegfilgrastim is in maintaining a healthy level of neutrophils in patients with severe chronic neutropenia who are already receiving daily treatment with another medication called G-CSF and anti-infective therapy. The study will observe patients over a period of time to see if pegfilgrastim can help keep their neutrophil levels above a certain threshold, which is important for reducing the risk of infections.

Participants in the study will receive pegfilgrastim as a solution for injection, administered under the skin. The study will monitor the number of infections, the use of antibiotics, and any hospitalizations that occur during the study period. This information will help determine the effectiveness of pegfilgrastim in managing severe chronic neutropenia. The study is expected to continue until 2030, providing valuable insights into the long-term benefits of this treatment.

]]> Study on the Use of Empagliflozin for Treating Neutropenia in Patients with Glycogen Storage Disease Type Ib https://clinicaltrials.eu/trial/study-on-the-use-of-empagliflozin-for-treating-neutropenia-in-patients-with-glycogen-storage-disease-type-ib/ Wed, 29 Apr 2026 15:02:10 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-empagliflozin-for-treating-neutropenia-in-patients-with-glycogen-storage-disease-type-ib/ This clinical trial is focused on studying a very rare inherited disease called Glycogen Storage Disease Type Ib (GSD Ib). This condition affects the body’s ability to store and use sugar properly, leading to a shortage of a type of white blood cell called neutrophils, a condition known as neutropenia. Neutrophils are important for fighting infections, so people with GSD Ib can be more prone to infections.

The study is testing a medication called empagliflozin, which is usually used to treat diabetes, to see if it can help increase the number of neutrophils in patients with GSD Ib. The purpose of the study is to evaluate the safety and how well patients tolerate empagliflozin when used for treating neutropenia in GSD Ib. Some participants will receive empagliflozin, while others may receive a placebo. The study will monitor participants over a period to see if empagliflozin helps restore neutrophil numbers and function.

Participants in the study will take the medication in the form of film-coated tablets. The study will involve regular visits to monitor the safety of the treatment and to check for any side effects. The goal is to gather information on how safe empagliflozin is for patients with GSD Ib and whether it can effectively help manage neutropenia in these patients.

]]> Study on the Effects of Amikacin Sulfate and Protective Isolation in Critically Ill Neutropenic Patients with Sepsis https://clinicaltrials.eu/trial/study-on-the-effects-of-amikacin-sulfate-and-protective-isolation-in-critically-ill-neutropenic-patients-with-sepsis/ Wed, 29 Apr 2026 15:01:06 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-amikacin-sulfate-and-protective-isolation-in-critically-ill-neutropenic-patients-with-sepsis/ This clinical trial is focused on studying the effects of a treatment for patients who are critically ill and have a condition called sepsis. Sepsis is a serious illness that occurs when the body has an extreme response to an infection, which can lead to tissue damage, organ failure, and even death. The study involves patients who are in intensive care and have a weakened immune system, a condition known as neutropenia. Neutropenia means having a very low number of a type of white blood cell called neutrophils, which are important for fighting infections. This condition can be caused by cancer or its treatment.

The treatment being studied includes the use of a medication called amikacin sulfate, which is an antibiotic that belongs to a group of drugs known as aminoglycosides. Antibiotics are medicines used to treat infections caused by bacteria. In this study, amikacin sulfate is given to patients through a vein, a method known as intravenous use. The purpose of the study is to see if adding amikacin sulfate to the usual antibiotic treatment can improve the outcomes for these patients. Additionally, the study is looking at whether not using protective isolation, a practice where patients are kept separate to prevent infections, affects the patients’ recovery.

The study will follow patients for a period of time to observe their health outcomes, including survival rates and any side effects they may experience. Researchers will also monitor the occurrence of kidney problems, hearing loss, and other serious health events. The goal is to understand if the combination of treatments can help reduce the risk of death and improve recovery in patients with sepsis and neutropenia. The study is expected to continue until 2025, and the findings will help guide future treatments for critically ill patients with these conditions.

]]>